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Insulin Resistance and
Ischemic Myocardial
Injury Post-Percutaneous
Coronary Interventions*
Peter W. F. Wilson, MD
Atlanta, Georgia
The paper by Uetani et al. (1) in this issue of JACC:
Cardiovascular Interventions reports that a greater degree of
insulin resistance is associated with worse short-term and
long-term cardiovascular disease (CVD) outcomes in Japa-
nese patients who underwent elective percutaneous coronary
interventions (PCI) with a drug-eluting stent (DES). The
investigators used the homeostasis model to assess insulin
resistance (HOMA-IR), which was calculated by multiply-
ing fasting glucose by fasting insulin and dividing by a
constant. Assessment of insulin resistance with this method
has typically been highly correlated with the gold standard
euglycemic-hyperinsulinemic clamp (2– 4); and the
HOMA-IR approach is practical in a clinical setting. The
investigators also assessed myocardial injury shortly after
the procedure by measuring troponin T and creatine
kinase myocardial band lysozyme biomarkers.
See page 1159
Some of the results from this study could easily be
anticipated by examining the characteristics of the study
participants. Their average age was approximately 70 years,
most were men, hypertension was extremely prevalent, and
approximately 50% had diabetes mellitus. The participants
seemed to generally harbor traits associated with the meta-
bolic syndrome, which is characterized by greater adiposity,
impaired fasting glucose or diabetes mellitus, elevated blood
pressure, low HDL, and elevated triglycerides. By contrast,
body mass index levels in the participants were generally
low.
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anticipated. The elective PCI procedure was followed by
elevated troponin T and creatine kinase levels in many subjects,
and evidence of myocardial injury after PCI was found to be
present to a greater degree in persons with more insulin resistance.
Many investigators have used metabolic syndrome traits
as indicators of insulin resistance and showed greater risk for
CVD events in association with a greater burden of meta-
bolic syndrome traits (5). As can be seen in the Uetani data,
the standard definition of the metabolic syndrome, even
with special provisions for making the diagnosis in an Asian
population, might not have identified the persons at high
risk for myocardial damage after stent placement or those
who experienced CVD events during the 2-year follow-up
interval. This study provides convincing evidence that al-
tered glucose and insulin metabolism act in concert to
increase the risk for CVD (3). These HOMA-IR data help
to identify persons at greater risk for myocardial damage
after the procedure and for greater clinical CVD risk during
2 years of follow-up. Similar data have been reported in the
past for the development of first coronary artery disease
(CAD) events in healthy populations (6,7). Additionally,
higher levels of insulin resistance have been shown to be
predictive of greater risk for recurrent angina pectoris in
persons who have undergone PCI with DES placement (8).
More severe coronary atherosclerosis is associated with
insulin resistance (9); and assessments that have been
undertaken in subjects who were suspected to have clinical
CAD and were studied with quantitative coronary angiog-
raphy are illustrative. Finnish investigators have compared
angiographic findings with a reference group of nondiabetic
persons without insulin resistance, and they found more
severe distal CAD lesions in nondiabetic subjects with
insulin resistance as well as in persons known to be diabetic
(10). Intravascular ultrasound was used to undertake these
investigations, and remodeling was considered present if
there was5% difference in lumen diameter compared with
a proximal coronary artery reference segment (11). Remod-
eling of coronary vessels has also been associated with
insulin resistance, and it has been thought that insulin
might affect vascular wall smooth muscle cell proliferation
and augment CAD risk synergistically with the renin-
angiotensin system.
It has been difficult to identify successful treatment
strategies that reduce insulin resistance and concomitantly
reduce risk for CVD events. Most oral hypoglycemic agents
do not have major effects on insulin resistance. The thiazo-
lidinediones have been shown to reduce insulin resistance
and in some cases to reduce atherosclerotic disease but these
agents have been associated with increased risk of cardiac
failure, and the total CVD risk–benefit ratio has not been
favorable (12). Newer therapeutic strategies that might affect
glycemia, insulin resistance, and inflammation are being eval-
uated and include novel agents, such as interleukin-1-beta
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1169neutralizing antibody and the newer hypoglycemic treatments,
such as glucagon-like peptide inhibitors and inhibitors of the
enzyme dipeptidyl peptidase IV (9).
The American Heart Association and the American
Diabetes Association have issued a joint scientific statement
that urges comprehensive risk assessment, lifestyle manage-
ment, and assiduous attention to risk factor control (13).
The prevention efforts have generally focused on reducing
risk for first CVD events, but an increasingly large number
of insulin-resistant and diabetic patients have prevalent
CVD, which places them at extremely high levels of risk for
subsequent CVD events (13). Unfortunately, the report by
Uetani does not provide information beyond the baseline
assessment of cardiovascular risk factors. Post-procedure
cigarette smoking, blood pressure control, and lipid levels
are important CVD risk determinants in patients who have
undergone PCI. Furthermore, it would be of interest to
have information on glycosylated hemoglobin (HbA1C)
levels in the post-hospital-stay interval. The Uetani study
participants had excellent HbA1C control at the time of
PCI, but it is possible that such good control was not
maintained during the follow-up period. Intensive glucose
control and very low HbA1C levels do not necessarily
reduce CVD risk, and diabetic patients in the ACCORD
and ADVANCE clinical trials with very low HbA1C levels
experienced greater risk for adverse CVD outcomes during
follow-up (14,15).
Determining the level of insulin resistance helps to
characterize persons with moderate-to-severe abnormalities
of glucose, insulin, and fat metabolism. Such assessments
have generally been reserved for clinical research, and provide
clues to improve identification of persons at greater CVD risk
over the near-term and longer-term post-PCI. Optimizing
such strategies and potentially developing and implementing
newer therapeutic approaches might help to improve risk for
CVD outcomes in the future for PCI patients.
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